Protocol Review and Monitoring System ABSTRACT The City of Hope Comprehensive Cancer Center (COHCCC) has a well-established system for review, oversight, and support of cancer research conducted by its investigators. The system includes review by (1) Multidisciplinary Disease and Modality Teams for City of Hope (COH) investigator initiated concepts; (2) the Cancer Protocol Review and Monitoring Committee (CPRMC); (3) the Data Safety Monitoring Committee (DSMC); and (4) the COH designated Institutional Review Boards. The offices that support these committees are centralized within COH?s Research Protections Unit and respectively include the Protocol Scientific Review and Monitoring Office (PSRMO), the Data and Safety Monitoring Office (DSMO); and the Office for Human Research Subject Protections (OHRSP). The COHCCC Protocol Review and Monitoring System (PRMS) is focused on the scientific merit of protocols, prioritization and feasibility of trial completions, as well as oversight of the progress of approved research and termination of research that no longer meets criteria for ongoing continuation. The PRMS is overseen by the CPRMC, which coordinates with investigators and multidisciplinary Disease and/or Modality Teams. The CPRMC is administratively supported by the PSRMO. All proposed cancer research must be reviewed and approved by the CPRMC either through a convened review process or through expedited administrative scientific review for prioritization, as permitted by the CCSG for peer-reviewed research, and reviewed for scientific progress on at least an annual basis. The CPRMC has authority to close trials that do not demonstrate scientific progress, and all appeals are evaluated by the CPRMC. The PRMS continues under the leadership of Karen Reckamp, MS, MD, who has chaired the CPRMC since 2012. Dr. Reckamp is appointed by and reports directly to the Cancer Center Director. The PSRMO is under the direction of Amanda Hammond, JD, Sr. Director of the Research Protections Unit who reports to Ashley Baker Lee, COH?s Senior Vice President for Research Operations. The PRMS was conditionally approved in 2012 and received full approval in 2014.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA033572-37
Application #
9849219
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2019-12-01
Budget End
2020-11-30
Support Year
37
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Beckman Research Institute/City of Hope
Department
Type
DUNS #
027176833
City
Duarte
State
CA
Country
United States
Zip Code
91010
Liu, Stephen V; Groshen, Susan G; Kelly, Karen et al. (2018) A phase I trial of topotecan plus tivantinib in patients with advanced solid tumors. Cancer Chemother Pharmacol 82:723-732
Maestrini, Davide; Abler, Daniel; Adhikarla, Vikram et al. (2018) Aging in a Relativistic Biological Space-Time. Front Cell Dev Biol 6:55
Adamus, Tomasz; Kortylewski, Marcin (2018) The revival of CpG oligonucleotide-based cancer immunotherapies. Contemp Oncol (Pozn) 22:56-60
Chaurasiya, Shyambabu; Chen, Nanhai G; Fong, Yuman (2018) Oncolytic viruses and immunity. Curr Opin Immunol 51:83-90
Chen, Steven F; Liu, Zheng; Chaurasiya, Shyambabu et al. (2018) Identification of core aberrantly expressed microRNAs in serous ovarian carcinoma. Oncotarget 9:20451-20466
Petrossian, Karineh; Nguyen, Duc; Lo, Chiao et al. (2018) Use of dual mTOR inhibitor MLN0128 against everolimus-resistant breast cancer. Breast Cancer Res Treat 170:499-506
Murray, Jennifer; Whitson, Robert H; Itakura, Keiichi (2018) Reduced prostaglandin I2 signaling in Arid5b-/- primary skeletal muscle cells attenuates myogenesis. FASEB J 32:1868-1879
Dufva, Olli; Kankainen, Matti; Kelkka, Tiina et al. (2018) Aggressive natural killer-cell leukemia mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target. Nat Commun 9:1567
Li, Daneng; McCall, Linda M; Hahn, Olwen M et al. (2018) Identification of risk factors for toxicity in patients with hormone receptor-positive advanced breast cancer treated with bevacizumab plus letrozole: a CALGB 40503 (alliance) correlative study. Breast Cancer Res Treat 171:325-334
Aslamy, Arianne; Oh, Eunjin; Ahn, Miwon et al. (2018) Exocytosis Protein DOC2B as a Biomarker of Type 1 Diabetes. J Clin Endocrinol Metab 103:1966-1976

Showing the most recent 10 out of 1396 publications